:: Volume 22, Issue 2 (4-2024) ::
Int J Radiat Res 2024, 22(2): 403-409 Back to browse issues page
Estrogen receptor ER-α36: A diagnostic biomarker for endometrial cancer
F. Li , L. Li , H. Li
The Fourth Hospital of Shijiazhuang, Shijiazhuang, Hebei, 050000, China , 13472192605@163.com
Abstract:   (2221 Views)
Background: In this experiment, we intend to investigate the relationship between ER-α36 expression and endometrial cancer. Materials and Method: A total of 172 healthy control and endometriosis patients were selected from our hospital. These included 43 cases of normal endometrium (NE group), 43 cases of endometrium without atypical hyperplasia (EH group), 43 cases of atypical hyperplasia (AH group) and 43 cases of endometrial cancer (EC group). The expression of ER-α36 in these tissues was detected by immunohistochemical methods. Results: The positive rate of estrogen receptor (ER-α36) in each group was 4.24%±5.02%, 5.74%±6.34%, 9.69%±9.42%, and 11.78%±10.39%, respectively. The expression of ER-α36 demonstrated a notably higher level in the AH and EC groups compared to the EH and NE groups. A statistically significant difference was observed between the NE group and the AH group (P=0.0112). The NE group was statistically different from the EC group (P=0.0001).There was a statistical difference between the EH group and the EC group (P=0.0040). Among endometrial cancers, the mean positive rate of ER-α36 expression was 11.67%±6.74% in highly differentiated endometrial cancers, 9.45%±11.38% in moderately differentiated, and 14.82%±11.35% in poorly differentiated. Comparison between the two groups showed that there was no statistically significant difference in the expression positivity rate of ER-α36 in endometrial cancer of different degrees of differentiation (P>0.05). Conclusion: ER-α36 has a certain diagnostic efficacy for endometrial cancer and can be used as an auxiliary judgment tool for pathological examination.
Keywords: ER-α36, diagnosis, endometrium cancer.
Full-Text [PDF 740 kb]   (723 Downloads)    
Type of Study: Original Research | Subject: Radiation Biology
References
1. Wang J, Zhang J, Meng Q, et al. (2022). Progress in the study of genes related to malignant biological characteristics of endometrial cancer. Shandong Medicine, 28: 109-112.
2. Zhou T X, Peng M, He X Q, et al. (2021) miR-373 targeted regulation of homologous heterozygous cassette gene B3 expression affects the biological properties of endometrial cancer Ishikawa cells. Anhui Medicine, 07: 1323-1327.
3. Wang J, Li Y, He HN, et al. (2023) Relationship of miR-141-3p and miR-149-3p expression in endometrial cancer tissues with proliferative genes, clinicopathologic features and prognosis. Int J Laboratory Medicine, 1-11.
4. Liu XH and Su YJ (2023) Comparison of outcomes between laparoscopic and open hysterectomy for early endometrial cancer. Clinical Medical Engineering, 12: 1645-1646.
5. Shi SL, Yang YL, Chen SP, et al. (2023) Analysis of risk factors for extrauterine dissemination and metastasis of endometrial cancer tumor cells confined to the uterus. China Medical Guide, 23: 5-8.
6. He ZX (2023) Effect of high potency progestin combined with long course paclitaxel+lopatin chemotherapy regimen on the efficacy and serum tumor markers of endometrial cancer patients. Heilongjiang Medical Science, 04:118-120.
7. Zhu XY, Lin YX, Xie JY, et al. (2023) Current status of RNA m6A modification in the progression and diagnostic evaluation of endometrial cancer. Int J Laboratory Medicine, 17: 2144-2149.
8. Chen YH, Yang HC, Luo Q, et al. (2023) Application value of serum HE4 and CA125 combined with plasma D-dimer assay in the diagnosis of endometrial cancer. China Health Standard Management, 19: 46-49.
9. Yu J (2022) Biomarkers and potential drug targets in gynecologic tumors. Doctoral dissertation, Peking :union: Medical College.
10. He Y, Wang T, Hu YJ (2019) Molecular typing characteristics and therapeutic value of endometrial cancer. Journal of Practical Obstetrics and Gynecology, 7: 505-508.
11. Lv JJ, Jin SL, Li YF (2023) Research progress on molecular typing of endometrial cancer. Health Research, 5: 556-559.
12. Hou JF, Jing T, Zhang HX (2021) Expression of estrogen receptor and progesterone receptor in endometrial cancer and its relationship with clinical features and prognosis. Cancer Progress, 18: 1874-1877+1929.
13. Jiang P Hu CY (2021) Prognostic value of immunohistochemical parameters of estrogen receptor and progesterone receptor in endometrial cancer. J Chongqing Medical University, 6: 708-715.
14. Tong JS (2021) Function of ER-α 36 in endometrial cancer and Icaritin-induced. Jilin University.
15. Yi QL, Jiang P, Zhu MQ, et al. (2023) Prognostic value of quantitative expression of immunohistochemical marker p53 in stage I-II endometrial cancer. Chinese Journal of Practical Gynecology and Obstetrics, 5: 568-572.
16. Du WK, Zhang YY, Du W (2021) miR-206 inhibits estrogen-induced proliferation and invasion of ER-α36-positive gastric cancer BGC-823 cells by targeting CDK14. Chinese Journal of Tumor Biotherapy, 7:689-695.
17. Xu XF, Wu SS, Wang H, et al. (2018) Progress in the study of molecular structure and related signaling pathways of membrane-type estrogen receptor ER-α36. Shandong Medicine, 19: 95-97.
18. Bonkhoff H (2018) Estrogen receptor signaling in prostate cancer: Implications for carcinogenesis and tumor progression. Prostate, 78(1): 2-10. [DOI:10.1002/pros.23446]
19. Cheng TD, Darke AK, Redman MW, et al. (2018) Somking, sex, and non-small cell lung cancer: Steroid hormone receptors in tumor tissue. Journal of the National Cancer Institute, 110(7): 734-742. [DOI:10.1093/jnci/djx260]
20. Ge H, Yan Y, Tian F, et al. (2018) Prognostic value of estrogen receptor α and estrogen receptor β in gastric cancer based on a meta-analysis and The Cancer Atlas (TCGA) datasets. International Journal of Surgery, 53: 24-31. [DOI:10.1016/j.ijsu.2018.03.027]
21. Wu C and Liao Q P (2018) Expression of estrogen receptor subtype mRNA in endometrial cancer tissues. Chinese Clinics of Obstetrics and Gynecology, 3: 198-200.
22. Wei YN, Wang YH, Chen R (2023) Study on the expression level and clinical significance of CRIM1 in tissues of type I endometrial cancer and precancerous lesions. Chinese Journal of Eugenics and Genetics, 31(9): 1833-1838.
23. Shen JY, Li CY, Jiang K, et al. (2021) Correlation of single nucleotide polymorphisms in the ERα gene with endometriosis induced by endocrine therapy drugs for breast cancer. Medical Herald, 40(01): 81-86.
24. Qiu LN (2020) Analysis of risk factors of endometrial cancer in patients with atypical endometrial hyperplasia. Fujian Medical University.
25. Li DD, Jing XJ, Liu T, et al. (2022) Effect of obesity on survival prognosis of endometrial cancer patients. Advances in Modern Obstetrics and Gynecology, 6: 422-428.

XML     Print

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 22, Issue 2 (4-2024) Back to browse issues page